Closed · CDC-RFA-PS21-2103 · CFDA 93.270 · Discretionary
Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments
Federal grant opportunity posted by Centers for Disease Control - NCHHSTP, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- December 1, 2020
- Close date
- 58
- Expected awards
The verdict
Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments is a closed discretionary listing from Centers for Disease Control - NCHHSTP that offered Varies by applicant across 58 expected awards. Future funding cycles may be published under the same CFDA number.
- Varies
- award range
- Closed
- application status
- 58
- expected awards
- 93.270
- CFDA program
Opportunity snapshot. This Grants.gov announcement - Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments - is cataloged under number CDC-RFA-PS21-2103 and tied to CFDA assistance listing 93.270, posted by Centers for Disease Control - NCHHSTP. Grants.gov currently shows the opportunity as closed, first posted on August 25, 2020 and last updated on October 22, 2020. The funding category is Discretionary, delivered as a cooperative agreement.
Award economics. The award range on file is Varies by applicant. The agency has projected $341.0 million in total estimated funding for this announcement. It expects to issue 58 awards. If the agency funds the expected 58 awards from the $341.0 million estimated pool, the average award works out to roughly $5.9 million. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity closed on December 1, 2020. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.
Award Range
Varies by applicant
Close Date
December 1, 2020
Electronically submitted applications must be submitted no later than 11:59 p.m., ET, on the listed application due date.
Posted
August 25, 2020
Est. Total Funding
$341,020,000
Expected Awards
58
Instrument
Cooperative Agreement
Description
This NOFO supports integrated viral hepatitis surveillance and prevention programs in states and large cities in the United States. Key strategies include viral hepatitis outbreak planning and response; and surveillance for acute hepatitis A, B and C, and chronic hepatitis C. Recipients should develop a jurisdictional viral hepatitis elimination plan, increase comprehensive hepatitis B and C reporting, improve HBV and HCV testing and increase healthcare providers trained to treat hepatitis B and C. Contingent on funding, the following activities can be supported: surveillance for chronic hepatitis B and perinatal hepatitis C; increased hepatitis B and C testing and referral to care in high-impact settings (syringe services programs (SSPs), substance use disorder (SUD) treatment centers, correctional facilities, emergency departments and sexually transmitted disease clinics; and increased access to services preventing viral hepatitis and other infections among people who inject drugs (PWID). Contingent on funding, an optional component will support improved access to prevention, diagnosis, and treatment of viral, bacterial and fungal infections related to drug use in settings disproportionately affected by drug use. Expected outcomes include improved surveillance for viral hepatitis, increased stakeholder engagement in viral hepatitis elimination planning, and improved access to viral hepatitis prevention, diagnosis, and treatment among populations most at risk.
Eligibility
Grants.gov lists this opportunity under eligibility category codes 00, 01, 02, 04. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
Gilberto Ramirez GHR0@cdc.gov
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
Related
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |